Amplia Therapeutics Limited (ASX:ATX)
Australia · Delayed Price · Currency is AUD 0.1250
-0.0050 (-3.85%)
At close: Dec 5, 2025
Amplia Therapeutics Revenue
Amplia Therapeutics had revenue of 2.63M AUD in the half year ending September 30, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to 5.01M, up 46.79% year-over-year. In the fiscal year ending March 31, 2025, Amplia Therapeutics had annual revenue of 3.78M, down -15.03%.
Revenue (ttm)
5.01M
Revenue Growth
+46.79%
P/S Ratio
12.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
64.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.78M | -669.04K | -15.03% |
| Mar 31, 2024 | 4.45M | 3.26M | 274.34% |
| Mar 31, 2023 | 1.19M | -793.83K | -40.03% |
| Mar 31, 2022 | 1.98M | 449.80K | 29.33% |
| Mar 31, 2021 | 1.53M | 1.50M | 4,380.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Amplia Therapeutics News
- 4 months ago - Bell Potter kicks off equity raisings for Amplia, Elsight - The Australian Financial Review